In summary, combined both GLP-1 RA and basal insulin therapy showed a significant improvement of glycemic indices, cardiovascular benefits, and GV among patients with uncontrolled T2D on previous therapy with premixed insulin. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.